Company / Cash & Equivalents
NovaBay Pharmaceuticals, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$430.0K
FY2024
5-year range
$430.0K / $12.0M
FY2020-FY2024
Trend
-85.3%
vs FY2023
Sector context
#209 of 209
Health Care
What the data says
Among 209 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 0% for cash & equivalents. Cash & Equivalents has declined for 4 consecutive years, from $12M in FY2020 to $430,000 in FY2024.
Based on SEC 10-K filings.
$430,000 in FY2024 with a 5-year CAGR of -42.7%.
Declined from $5M to $430,000 over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -61.4%
- 5-Year CAGR
- -42.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 209This company $430.0K Sector average $696.0M
▼
-99.9% below sector average
Key checks
Key Insights
- NovaBay Pharmaceuticals, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -42.7%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 85.3% year-over-year.
- Ranks #209 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $430.0K | -85.3% |
| FY2023 | $2.9M | -45.5% |
| FY2022 | $5.4M | -28.5% |
| FY2021 | $7.5M | -37.2% |
| FY2020 | $12.0M | +72.3% |
| FY2019 | $6.9M | +117.9% |
| FY2018 | $3.2M | -0.5% |
| FY2017 | $3.2M | -66.4% |
| FY2016 | $9.5M | +298.8% |
| FY2015 | $2.4M | -56.1% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026